Connect with us

Cannabis News

GOP Congressman Says His Hemp Regulation Bill Faces Opposition From Alcohol, Marijuana And Prohibitionist Groups

Published

3 weeks ago

on

A congressional Republican who plans to immediately introduce legislation to federally regulate hemp-derived products instead of a ban that would take effect this year says the plan is opposed by a coalition of odd bedfellows that includes the alcohol industry, marijuana companies and opponents of cannabis legalization.

Rep. Andy Barr (R-KY) said during a Zoom meeting Thursday with members of the Hemp Industry & Farmers of America (HIFA) that his bill would create a “regulatory and tax framework” that would “provide a lifeline and … a permanent legal pathway to this market,” according to a transcript obtained by Marijuana Moment.

Hemp derivatives containing less than 0.3 percent delta-9 THC by dry weight were made federally legal under the 2018 Farm Bill signed by President Donald Trump in his first term. But late last year, Trump signed new legislation containing provisions that will redefine hemp so that only products with a total of 0.4 milligrams of THC per container will be legal starting Nov. 12.

Barr said the recriminalization of THC hemp products would “jeopardize the crop that’s being stored right now” after farmers grow it and thwart “future opportunities to grow this crop.”

“That’s why we need this legislation to establish a regulatory framework and create parity with other similar products, especially in the beverage category,” he said, according to a transcript of the meeting. “We want to create a level playing field with other adult beverages so that farmers have the confidence to be able to sell in a mature market with protections that achieve what we want to achieve (for safety, targeting age consumers, but also supporting our farmers all the way).

But the effort faces opposition not only from prohibitionist forces, but also from segments of the alcohol industry and marijuana businesses that sell cannabis products under limited state-based licensing systems, according to congress.

Distilled spirits producers have “understandable concerns about competition” from hemp-derived THC drinks, Barr said. He added that companies at the wholesale level of the alcohol industry could be an ally because they “want to distribute” cannabis drinks.

“I think the wholesaler wants a three-tiered system, so we’ve worked to try to get that, again, with a one-to-one, where there would be direct-to-consumer exemptions, where it would make sense to be on a state-by-state basis,” he said.

“We recognize that the spirits and other adult beverage groups don’t want competition. That’s natural. But what we want is regulation and taxation… We want a level playing field. Competition and choice is something I believe in. And giving consumers choices. Competition is good… You’re looking at one of the bourbon industry’s staunchest advocates for choice, I think he might be pro-hemp and pro-Kentucky bourbon.

“Then you have prohibitions,” said the congressman. “And they are there, and they may not be convincing, but they exist.”

“And finally, there’s another category, and that’s the marijuana industry that also sees it as competition,” Barr said, according to a transcript of the meeting. “They’re going to want to push the industry into specialized dispensaries. My view is that it’s not the same. Maybe that’s right for the marijuana industry, but I don’t think that’s right for this hemp-derived products industry.”

Barr’s next bill, called the “Hemp Protection Act” in drafts seen by Marihuana Moment, would impose age-restricted labeling requirements on hemp products, subject to Food and Drug Administration (FDA) oversight. There would also be taxes on hemp products administered by the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau (TTB).

Meanwhile, White House officials recently briefed Barr’s office on pending legislation to create a regulatory framework for hemp..

Last month, Vince Haley, director of the White House Domestic Policy Council, and James Braid, assistant to the president for legislative affairs, sent hemp policy suggestions to the congressman’s office.

“We appreciate your work to advance policy,” the executive order Trump signed in December, which included provisions to protect Americans’ access to CBD products, the staff wrote in a letter to Congress.

“We are submitting draft legislation and comments to your account to address the final statutory definition of hemp-derived cannabinoid products to ensure that Americans have access to adequate full-spectrum CBD products while maintaining Congress’ intent to limit the sale of products that pose serious health risks,” White House officials said, according to a social media screencast. “We are ready for further discussion and technical assistance.”

The annex to the administration’s proposed legislative text has not been released publicly, and the White House and Barr’s office did not respond to Marihuana Moment’s requests for more details.

During a meeting with representatives of hemp companies on Thursday, the congressman said there is a “tremendous opportunity” in agriculture, farming and this industry in general, according to the transcript.

“I’m from central Kentucky. All four of my grandparents were born and raised in central Kentucky. I grew up in central Kentucky. And at one time, that was the burley tobacco capital of the world. Since tobacco production has declined, our farmers have been looking for alternatives. And industrial hemp and hemp-derived products have created a tremendous opportunity and this market has created a tremendous opportunity. I look forward to consumers working with the industry to provide stability and certainty to the industry. for this to be properly seen as a mature industry, for the law to have some permanence and to reduce the uncertainty that exists today, so that this market can thrive.

Barr also said that cannabis products could provide a safer alternative to prescription drugs, especially for military veterans.

“To the extent that we can promote opioid alternatives or opioid avoidance and help veterans with anxiety or sleep deprivation or insomnia or post-traumatic stress disorder, that’s what we want to do, create those opportunities for our veterans to care for them,” he said. “We think this is a great opportunity for our veteran community.”

HIFA officials on the call said they expect Barr’s bill to be introduced next week, although the proposed deadline for the legislation has already been pushed back several times in recent weeks as Barr has engaged with stakeholders, tweaked draft provisions and sought initial sponsors to introduce the proposal.

The House of Representatives recently a Farm Bill with provisions to support producers of industrial hemp—but without any language delaying or changing the federal recriminalization of THC hemp products that takes effect in November.

Trump last month It inspired lawmakers in Congress to take action to change the currently planned hemp banwhich suggested that full-spectrum CBD products threaten to be federally recriminalized.

“I’m calling on Congress to update the Act so Americans can continue to have access to the full-spectrum CBD products they trust and support, while maintaining Congress’ intent to restrict the sale of products that pose health risks,” the president said in a Truth Social message Thursday, the same day his administration announced it is moving forward to re-regulate marijuana.

“We need to do this RIGHT and FAST, especially for those who have found CBD to help them,” he said. “Also, I’m told it will help our BIG FARMERS that we love and will always be around.”

The main retailer Target, meanwhile, recently moved to expand sales of hemp THC drinks to more states.

The Wine & Spirits Wholesalers of America (WSWA), for its part, according to the House Failure to include provisions to delay or modify the ban on THC hemp products was a “missed opportunity.”

“A ban will not take these products off the market, it will push consumers into unregulated online channels without age verification, product standards or accountability,” said Dawson Hobbs, WSWA executive vice president of government affairs.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Related Topics:
Continue Reading

Cannabis News

Concert Series Specials launched for state medical cannabis patients

Published

10 hours ago

on

June 8, 2026

By











Post Dispensary, Kentucky’s first medical cannabis dispensary, is connecting with patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Madisonville, Hopkinsville and surrounding areas by aligning unique specials with the region’s summer concert calendar. Located at 300 N Main St. in Beaver Dam, minutes from major highways connecting these vibrant cities.

This summer, The Post Dispensary is offering special pricing and incentives for Concert Series Events at the Beaver Dam Amphitheater, SPARKS in the Park 4th of July celebration and surrounding events, such as Owensboro’s ROMP Festival (June 24-27, 2026). Patients can stop by before or after shows for big savings.

“We’re more than just a booty,” said a dispensary representative. “From Owensboro’s world-class ROMP Festival to Beaver Dam’s Amphitheater events, we’re making it convenient and budget-friendly for patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Hartford and beyond to combine our love of music with compassionate care and an affordable product.”

The Post Dispensary hosts regular Patient Guidance events on the second Saturday of every month. These units have professionals on hand to assess patients and issue written certificates at low cost, application support and expert consultations in a welcoming environment. The next Patient Drive aligns perfectly with summer travel patterns, making it easy for patients from Owensboro, Bowling Green, Elizabethtown, Madisonville, Henderson, Madisonville and surrounding towns to plan a trip to Beaver Dam that combines care with community and entertainment.

For more information:
Post-Dispensary
thepostdispensary.com/










Continue Reading

Cannabis News

Missouri GOP Lawmakers Hope Trump’s Psychedelics Order Boosts Efforts To Allow Military Veteran Access In The State

Published

10 hours ago

on

June 8, 2026

By

“Congratulations to President Trump for stepping up and taking the lead on this. PTSD is a killer among veterans.”

By Rebecca Rivas, Missouri Independent

Missouri state representative Dave Griffith has spent the past five years researching how psychedelic-assisted therapy has helped veterans struggling with post-traumatic stress disorder and depression.

His last legislative session in the House ended this May, and he pushed legislation for the last time allow clinical trials of psychedelic-assisted therapy in Missouri. In the final days of the session, the bill stalled in the Missouri Senate after passing the House with overwhelming support.

“I’m not going to be there next year, I’m term-limited,” said Griffith, a Republican who served as chairman of the House Veterans Affairs and Armed Services Committee. “It’s really about passing the torch to a lot of other veterans who are on the Veterans Commission and see the value in that.”

He was hopeful when he saw an announcement The US Department of Veterans Affairs announced last week a new clinical trial to evaluate the safety and effectiveness of methylenedioxymethamphetamine-assisted therapy.or MDMA-assisted therapy. MDMA is a synthetic substance made in a laboratory, according to the department, and is also called “ecstasy” or “molly” in recreational use.

“Congratulations to President Trump for stepping up and taking the lead on this,” said Griffith of Jefferson City. “PTSD is a killer among veterans. If you just listen to the testimony that’s been happening over the last five years in the Missouri House, the life-changing it’s been for them is a compelling reason why something like this works.”

A new trial follows Trump signed an executive order in April, “Expediting Medical Treatment for Serious Mental Illness.” The order aims to increase participation in clinical trials and accelerate innovative research models and drug approvals for psychedelics.

Directs the Secretary of Health and Human Services to allocate at least $50 million to support and collaborate with state governments that “have established or are developing programs to advance psychedelic drugs for serious mental illness.”

Without passing the legislation, Missouri will miss this opportunity, said Republican state representative Matthew Overcast of Ava.

Cloud hoped that Trump’s April order would help “grease the wheels” this year by state Rep. Richard West and state Rep. Richard West who sponsored the state to conduct a study on psilocybin and ibogaine therapy.

“The last couple of months there’s been a lot of feds on things that the states are reluctant to move forward with here,” Overcast said. “So it’s exciting.”

According to the VA’s announcement, the department is involved in 19 other active clinical trials focused on psychedelic therapies for mental health conditions that have received more than $23 million in outside funding.

The new trial, called “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in US Veterans,” will enroll about 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and those receiving the same psychotherapy with an active placebo. VA is coordinating with the US Food and Drug Administration and plans to share trial data with FDA.

The trial will be conducted at the VA Providence Healthcare System, and will recruit veterans from the Providence, Rhode Island, campus in West Haven, Connecticut, and the VA Connecticut Healthcare System.

Trump’s executive order says there have been more than 6,000 veteran suicides per year for more than 20 years, and the current veteran suicide rate is twice that of the adult non-veteran population.

He says people with major depressive disorder and substance abuse disorder, among other serious mental illnesses, may relapse or fail to respond fully to standard medical and psychiatric therapies.

“Despite significant federal investment in research into potential advances in mental health care and treatment, our medical research system has yet to produce approved therapies that promote lasting improvements in the mental health status of the most complex patients,” the order states. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription drugs.”

Missouri veterans John and Kara Grady, who own a hemp shop in Rosebud, strongly agree with the statement, they said. And they’d like to see Missouri’s veterans health system participate in clinical trials already underway.

“President Trump is opening up investigations for the veteran community,” said John Grady, “If you look at the numbers … we’ve lost more in the wars with mental health than we’ve lost.”

The lack of movement on psychedelic-assisted therapy legislation is among the reasons why John Grady is running for state representative over Bruce Sassmann in the state’s Republican primary.

“If you don’t agree with Trump on everything, at least he’s addressing this veteran issue right here,” Grady said. “Hopefully, we’ll be able to stop that number, we’ll stop that flow of our precious veterans dying by their own hands because they don’t have treatment.”

This story was first published by the Missouri Independent.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Germany’s medical cannabis imports post first quarterly decline since early 2024

Published

1 day ago

on

June 7, 2026

By

German imports of medical cannabis flowers fell to 50.5 tonnes in the first quarter of 2026, down from 60.8 tonnes in the previous quarter, the decline from the first quarter of 2024. According to a new EU and UK market update from Whitney Economics.

The drop lands against a year that went backwards. Germany took in more than 2025 tonnes of the product in 2025, more than double the 72,850 kilograms recorded in 2024, and import volumes have risen every year since 2018, when the figure remained below 4,500 kilograms. The first quarter number continues to match the high pace of 2025, which is why the report treats it as an early sign of stabilization rather than a turnaround.

Prices
The volume has not created a stable price. A gram of cannabis in a German pharmacy is approaching 4 euros, while a gram on the illegal market is around 8 euros, reversing the usual relationship between regulated and unregulated supply. The wholesale price is around 2 euros per gram, roughly half the retail price at the pharmacy. Pharmacy prices breached 3.99 euros in November 2025, and the report puts the overall compression close to 25% in two and a half years.

Germany legalized ownership in 2024 and restricted sales to pharmaceutical and telemedicine providers. Two access roads run parallel. Medical cannabis is mainly prescribed through private prescriptions, and recreational cannabis is available through membership of a cannabis association, with 400 licensed cultivation associations across the country, although the exact count varies by source. It is the medical segment that drives market growth, not the recreational segment.

Growth is based on telemedicine
 Patients fill out an online questionnaire, receive a prescription from an affiliated physician, and in many cases have their order filled through an integrated pharmacy partner, with delivery within days and, in some cities, within hours. Between 600,000 and 700,000 self-employed consumers are supported by the telemedicine industry, compared to 200,000 to 300,000 medical patients supported by pharmacies. Total imports are now sufficient to supply between 900,000 and one million consumers.

© Philiprowe | Dreamstime

Market exposure
Critics argue that commercial interests risk overshadowing the medical nature of the system, and treatment does not always meet the required standard of control. Legislative initiatives that would tighten the framework are already on the table, including mandatory in-person inquiries and a ban on distribution of mail requests. The likely result of both measures is a significant decline in demand for medical cannabis flowers. Many telemedicine companies are preparing for the opportunity by building networks with local doctors and pharmacies.

Where patients and consumers would go if medical access is curtailed is an open question, as the recreational market lacks a real alternative for patients and cannabis clubs continue to face licensing hurdles at the state level.

Part of the difficulty in reading the market is that import figures say less than they seem. More cannabis is entering the country than ever before, but how much is reaching consumers and what the actual demand is is unclear. Without a nationwide data framework, the market functions as a black box, and excess supply and actual demand are difficult to measure with great precision. Supply has tended to expand faster than the market can absorb, with no forecast to confirm mature demand, and prices have adjusted downward as a result.

Germany has had a signal effect across Europe since the start of its reform, although its model has drawn criticism, with the mixing of medical and recreational consumption a recurring complaint. Countries that have traditionally taken a conservative line, France among them, have gone to a more formalized medical field, under stricter conditions and without adopting the medical flower like Germany.

For more information:
Whitney Economics
Beau Whitney
(503) 724-3084
www.whitneyeconomics.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media